

Sabine Zchbauer-Mller

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5639040/sabine-zochbauer-muller-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76
papers

4,184
citations

32
h-index

64
g-index

78
ext. papers

4,651
ext. citations

6.4
avg, IF

4.58
L-index

#	Paper	IF	Citations
76	Influence of temporal muscle thickness on the outcome of radiosurgically treated patients with brain metastases from non-small cell lung cancer.. <i>Journal of Neurosurgery</i> , 2022 , 1-7	3.2	0
75	The impact of COVID-19 on cancer care of outpatients with low socioeconomic status.. <i>International Journal of Cancer</i> , 2022 ,	7.5	3
74	Neutrophil-to-Lymphocyte Ratio Is Superior to Other Leukocyte-Based Ratios as a Prognostic Predictor in Non-Small Cell Lung Cancer Patients with Radiosurgically Treated Brain Metastases Under Immunotherapy or Targeted Therapy. <i>World Neurosurgery</i> , 2021 , 151, e324-e331	2.1	2
73	Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. <i>Blood</i> , 2021 , 137, 1669-1678	2.2	44
72	Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients. <i>Journal of Neuro-Oncology</i> , 2021 , 151, 257-265	4.8	3
71	Gamma Knife Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy. <i>Cancers</i> , 2020 , 12,	6.6	4
70	Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma. <i>Thoracic Cancer</i> , 2020 , 11, 1979-1988	3.2	1
69	Systemic Inflammation and Activation of Haemostasis Predict Poor Prognosis and Response to Chemotherapy in Patients with Advanced Lung Cancer. <i>Cancers</i> , 2020 , 12,	6.6	11
68	Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. <i>ESMO Open</i> , 2020 , 5, e000880	6	1
67	Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study. <i>Oncologist</i> , 2020 , 25, e1930-e1955	5.7	4
66	Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non-small cell lung cancer brain metastases. <i>Cancer</i> , 2020 , 126, 4341-4352	6.4	15
65	Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy. <i>Lung Cancer</i> , 2020 , 148, 159-165	5.9	7
64	Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare Exon 20 Mutation. <i>Frontiers in Oncology</i> , 2020 , 10, 593852	5.3	8
63	Prognostic assessment in patients with newly diagnosed small cell lung cancer brain metastases: results from a real-life cohort. <i>Journal of Neuro-Oncology</i> , 2019 , 145, 85-95	4.8	6
62	SOCS2 is part of a highly prognostic 4-gene signature in AML and promotes disease aggressiveness. <i>Scientific Reports</i> , 2019 , 9, 9139	4.9	22
61	Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer. <i>British Journal of Haematology</i> , 2019 , 186, 311-320	4.5	49
60	DNA methylation of microRNA-coding genes in non-small-cell lung cancer patients. <i>Journal of Pathology</i> , 2018 , 245, 387-398	9.4	19

59	Trimodality therapy for Pancoast tumors: T4 is not a contraindication to radical surgery. <i>Journal of Surgical Oncology</i> , 2017 , 116, 227-235	2.8	5
58	SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers. <i>Molecular Cancer</i> , 2017 , 16, 1	42.1	90
57	Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients. <i>Oncotarget</i> , 2017 , 8, 81250-81260	3.3	12
56	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. <i>ESMO Open</i> , 2016 , 1, e000066 ⁶		14
55	Lung transplantation in patients with incidental early stage lung cancer-institutional experience of a high volume center. <i>Clinical Transplantation</i> , 2016 , 30, 912-7	3.8	6
54	Management of malignant pleural mesothelioma-part II: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG). <i>Wiener Klinische Wochenschrift</i> , 2016 , 128, 618-26	2.3	7
53	EV11 promotes tumor growth via transcriptional repression of MS4A3. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 28	22.4	20
52	Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. <i>Heart</i> , 2015 , 101, 1874-80	5.1	122
51	CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. <i>Blood</i> , 2015 , 125, 90-101	2.2	123
50	Epigenetic down-regulation of integrin β increases migratory potential and confers poor prognosis in malignant pleural mesothelioma. <i>Journal of Pathology</i> , 2015 , 237, 203-14	9.4	23
49	DNA methylation transcriptionally regulates the putative tumor cell growth suppressor ZNF677 in non-small cell lung cancers. <i>Oncotarget</i> , 2015 , 6, 394-408	3.3	18
48	Next Generation Sequencing Identifies DNA Methylation Patterns Indicative of Disease Progression in Ph+ CML. <i>Blood</i> , 2014 , 124, 4526-4526	2.2	
47	A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. <i>Cancer Cell</i> , 2013 , 24, 167-81	24.3	169
46	ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. <i>Lung Cancer</i> , 2013 , 80, 278-83	5.9	50
45	Genome-wide CpG island methylation analyses in non-small cell lung cancer patients. <i>Carcinogenesis</i> , 2013 , 34, 513-21	4.6	57
44	Retraction: DNA methylation profiles of lymphoid and hematopoietic malignancies. <i>Clinical Cancer Research</i> , 2013 , 19, 307	12.9	
43	Frequent overexpression of ErbB-receptor family members in brain metastases of non-small cell lung cancer patients. <i>Apmis</i> , 2013 , 121, 1144-52	3.4	12
42	5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand. <i>Blood</i> , 2012 , 119, 4242-52	2.2	33

41	Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. <i>Clinical Cancer Research</i> , 2012 , 18, 1619-29	12.9	134
40	c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5Sregion of Cdk6. <i>Blood</i> , 2011 , 117, 4065-75	2.2	29
39	Biochip-based detection of KRAS mutation in non-small cell lung cancer. <i>International Journal of Molecular Sciences</i> , 2011 , 12, 8530-8	6.3	4
38	Lung cancer: from single-gene methylation to methylome profiling. <i>Cancer and Metastasis Reviews</i> , 2010 , 29, 95-107	9.6	83
37	Epigenetic Approaches in Oncology 2010 , 195-208		
36	Comparison of Three Pain Assessment Tools in Oncological Patients during Palliative Chemotherapy-Implications for Clinical Practice. <i>Physikalische Medizin Rehabilitationsmedizin Kurortmedizin</i> , 2009 , 19, 326-332	0.5	2
35	Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008 , 135, 1036-41	1.5	36
34	Genome-wide transcriptional response to 5-aza-2Sdeoxycytidine and trichostatin a in multiple myeloma cells. <i>Cancer Research</i> , 2008 , 68, 44-54	10.1	138
33	Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia. <i>International Journal of Cancer</i> , 2007 , 121, 1984-93	7.5	50
32	Progressive up-regulation of genes encoding DNA methyltransferases in the colorectal adenoma-carcinoma sequence. <i>Molecular Carcinogenesis</i> , 2007 , 46, 766-72	5	28
31	JunB is a gatekeeper for B-lymphoid leukemia. <i>Oncogene</i> , 2007 , 26, 4863-71	9.2	20
30	Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007 , 103, 283-91	4.4	68
29	NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2006 , 45, 81-9	13.4	44
28	Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. <i>Oncogene</i> , 2006 , 25, 959-68	9.2	66
27	Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. <i>Oncogene</i> , 2005 , 24, 732-6	9.2	48
26	Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation. <i>Oncogene</i> , 2005 , 24, 6249-55	9.2	40
25	DNA methylation profiles of lymphoid and hematopoietic malignancies. <i>Clinical Cancer Research</i> , 2004 , 10, 2928-35	12.9	57
24	DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. <i>Cancer</i> , 2004 , 100, 2598-606	6.4	61

23	Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. <i>International Journal of Cancer</i> , 2003 , 103, 153-60	7.5	246
22	Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. <i>International Journal of Cancer</i> , 2003 , 107, 612-6	7.5	115
21	Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers. <i>Oncogene</i> , 2003 , 22, 1580-8	9.2	89
20	The impact of hemoglobin levels on fatigue and quality of life in cancer patients. <i>Annals of Oncology</i> , 2002 , 13, 965-73	10.3	106
19	Aberrant DNA methylation in lung cancer: biological and clinical implications. <i>Oncologist</i> , 2002 , 7, 451-7	5.7	115
18	Molecular pathogenesis of lung cancer. <i>Annual Review of Physiology</i> , 2002 , 64, 681-708	23.1	149
17	Future developments in the treatment of lung cancer. <i>Lung Cancer</i> , 2002 , 38 Suppl 3, S81-5	5.9	6
16	Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. <i>Clinical Cancer Research</i> , 2002 , 8, 514-9	12.9	214
15	Molecular genetic abnormalities in the pathogenesis of human lung cancer. <i>Pathology and Oncology Research</i> , 2001 , 7, 6-13	2.6	56
14	Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 691-9	9.7	637
13	Fragile histidine triad (FHIT) gene abnormalities in lung cancer. <i>Clinical Lung Cancer</i> , 2000 , 2, 141-5	4.9	25
12	Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 1303-7	9.7	302
11	Treatment of small cell lung cancer patients. <i>Annals of Oncology</i> , 1999 , 10 Suppl 6, 83-91	10.3	16
10	Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial. <i>European Journal of Cancer</i> , 1998 , 34, 1977-80	7.5	23
9	MDR1 RNA transcripts do not indicate long-term prognosis in colorectal carcinomas. <i>European Journal of Cancer</i> , 1997 , 33, 1516-8	7.5	4
8	Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. <i>Leukemia</i> , 1997 , 11, 639-43	10.7	90
7	Multidrug resistance in leukemias and its reversal. <i>Leukemia and Lymphoma</i> , 1996 , 23, 451-8	1.9	28
6	Adjuvant and Induction Chemotherapies in Non-Small-Cell Lung Cancer. <i>Oncology Research and Treatment</i> , 1996 , 19, 221-225	2.8	

5	Dexverapamil as resistance modifier in acute myeloid leukaemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 1995 , 121 Suppl 3, R21-4	4.9	6
4	MDR1 gene expression in lymphocytes of patients with renal transplants. <i>Nephron</i> , 1995 , 69, 277-80	3.3	24
3	MDR1 gene expression in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 1994 , 13, 333-8	1.9	11
2	MDR1 RNA expression as a prognostic factor in acute myeloid leukemia: an update. <i>Leukemia and Lymphoma</i> , 1993 , 12, 91-4	1.9	16
1	MDR1 gene expression in primary colorectal carcinomas. <i>British Journal of Cancer</i> , 1993 , 68, 691-4	8.7	28